Inventor · disambiguated record
Gerald W. Shipps, Jr.
Also filed as: SHIPPS GERALD · SHIPPS GERALD W · SHIPPS GERALD W JR · SHIPPS JR GERALD W
41 granted patents·12 pending applications·238 citations·filing 1998–2022
97Inventor score
Top patents by PatentIndex Score
53 records- 0193US11352356B2Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jun 7, 2022·4 cites·29 claims
- 0293US7807672B2Compounds that are ERK inhibitorsSCHERING CORP·Filed 2007·Granted Oct 5, 2010·16 cites·23 claims
- 0392US10730874B2Inhibitors of plasma kallikrein and uses thereofSHIRE HUMAN GENETIC THERAPIES·Filed 2019·Granted Aug 4, 2020·7 cites·18 claims
- 0490US7884107B2Substituted piperidines that increase P53 activity and the uses thereofMERCK·Filed 2007·Granted Feb 8, 2011·32 cites·36 claims
- 0588US9242981B2Fused pyrazole derivatives as novel ERK inhibitorsSHIPPS JR GERALD W·Filed 2011·Granted Jan 26, 2016·9 cites·2 claims
- 0688US8946216B2Indazole derivatives useful as ERK inhibitorsDENG YONQI·Filed 2011·Granted Feb 3, 2015·23 cites·13 claims
- 0786US8546404B2Compounds that are ERK inhibitorsCOOPER ALAN B·Filed 2007·Granted Oct 1, 2013·9 cites·76 claims
- 0885US9351965B2Indazole derivatives useful as ERK inhibitorsSHIPPS JR GERALD W·Filed 2011·Granted May 31, 2016·5 cites·2 claims
- 0985US8318735B22-aminothiazole-4-carboxylic amides as protein kinase inhibitorsSHIPPS JR GERALD W·Filed 2007·Granted Nov 27, 2012·10 cites·16 claims
- 1085US8227605B22-aminothiazole-4-carboxylic amides as protein kinase inhibitorsSHIPPS JR GERALD W·Filed 2007·Granted Jul 24, 2012·11 cites·17 claims
- 1184US7173046B2CD40:CD154 binding interrupter compounds and use thereof to treat immunological complicationsBIOGEN INC·Filed 2003·Granted Feb 6, 2007·22 cites·6 claims
- 1282US7652020B2Compounds for the treatment of inflammatory disordersSCHERING CORP·Filed 2005·Granted Jan 26, 2010·5 cites·48 claims
- 1379US11325903B2Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseasesBANTAM PHARMACEUTICAL LLC·Filed 2017·Granted May 10, 2022·2 cites·24 claims
- 1479US8278337B2Substituted pyridines that are JNK inhibitorsBELANGER DAVID B·Filed 2007·Granted Oct 2, 2012·8 cites·25 claims
- 1578US11602526B2Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating theretoBANTAM PHARMACEUTICAL LLC·Filed 2020·Granted Mar 14, 2023·1 cites·27 claims
- 1677US10537558B2Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating theretoBANTAM PHARMACEUTICAL LLC·Filed 2016·Granted Jan 21, 2020·3 cites·28 claims
- 1777US9206142B2Anilinopiperazine derivatives and methods of use thereofSHIPPS JR GERALD W·Filed 2007·Granted Dec 8, 2015·4 cites·21 claims
- 1877US7115749B2Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agentsSCHERING CORP·Filed 2005·Granted Oct 3, 2006·3 cites·30 claims
- 1976US8759357B2Inhibitors of fatty acid binding protein (FABP)SHIPPS JR GERALD W·Filed 2010·Granted Jun 24, 2014·6 cites·8 claims
- 2075US8591943B2Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitorsDENG YONGQI·Filed 2010·Granted Nov 26, 2013·6 cites·2 claims
- 2175US7196111B2Pyrazolo[1,5a]pyrimidine compounds as antiviral agentsSCHERING CORP·Filed 2003·Granted Mar 27, 2007·8 cites·2 claims
- 2273US8716483B2Compounds that are ERK inhibitorsCOOPER ALAN B·Filed 2009·Granted May 6, 2014·2 cites·12 claims
- 2371US12441724B2Inhibitors of plasma kallikrein and uses thereofTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Oct 14, 2025·0 cites·29 claims
- 2471US8815875B2Inhibitors of fatty acid binding protein (FABP)SHIPPS JR GERALD W·Filed 2009·Granted Aug 26, 2014·2 cites·11 claims
- 2569US7446195B2High affinity thiophene-based and furan-based kinase ligandsSCHERING CORP·Filed 2006·Granted Nov 4, 2008·1 cites·10 claims
- 2668US6207861B1Method for producing and screening mass coded combinatorial libraries for drug discovery and target validationNEOGENESIS INC·Filed 1998·Granted Mar 27, 2001·30 cites·15 claims
- 2766US8999966B2Compounds that are ERK inhibitorsBOGA SOBHANA BABU·Filed 2011·Granted Apr 7, 2015·1 cites·6 claims
- 2865US8859776B2Substituted piperidines that increase p53 activity and the uses thereofBOGEN STEPHANE L·Filed 2010·Granted Oct 14, 2014·2 cites·44 claims
- 2964US2023076820A1Substituted Pyrazole Compounds and Methods of Using Them for Treatment of Hyperproliferative DiseasesBANTAM PHARMACEUTICAL LLC·Filed 2022·Application pending·0 cites
- 3063US8889683B2Substituted quinoxalines as inhibitors of fatty acid binding proteinCHENG CLIFFORD·Filed 2011·Granted Nov 18, 2014·2 cites·9 claims
- 3163US7705127B1HDM2 PolypeptidesSCHERING CORP·Filed 2008·Granted Apr 27, 2010·0 cites·8 claims
- 3262US7269519B2Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validationSCHERING CORP·Filed 2003·Granted Sep 11, 2007·0 cites·23 claims
- 3359US8609675B2Fused Tricyclic Compounds as novel mTOR inhibitorsCHENG CLIFF C·Filed 2010·Granted Dec 17, 2013·1 cites·14 claims
- 3456US2008004286A1Method of Using Substituted Piperidines that Increase P53 ActivitySCHERING CORP·Filed 2007·Application pending·0 cites
- 3552US7888474B2HDM2 polypeptidesSCHERING CORP·Filed 2010·Granted Feb 15, 2011·0 cites·8 claims
- 3650US2014336222A1SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOFMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 3750US2007249682A1Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complicationsZHENG ZHONGLI·Filed 2007·Application pending·0 cites
- 3849US8394960B2Thiazole carboxamide derivatives and their use to treat cancerSHIPPS JR GERALD W·Filed 2008·Granted Mar 12, 2013·0 cites·14 claims
- 3948US7511063B2High affinity quinoline-based kinase ligandsSCHERING CORP·Filed 2006·Granted Mar 31, 2009·0 cites·51 claims
- 4048US2006063169A1Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validationNEOGENESIS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 4148US2010298314A1Novel jnk inhibitorsSCHERING CORP·Filed 2007·Application pending·0 cites
- 4244US7449488B2Pyrazolopyrimidines as protein kinase inhibitorsSCHERING CORP·Filed 2005·Granted Nov 11, 2008·0 cites·16 claims
- 4344US7425640B2Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agentsSCHERING CORP·Filed 2005·Granted Sep 16, 2008·0 cites·24 claims
- 4442US12150934B2Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseasesBANTAM PHARMACEUTICAL LLC·Filed 2017·Granted Nov 26, 2024·0 cites·31 claims
- 4542US9062071B2Substituted piperidines as HDM2 inhibitorsMERCK SHARP & DOHME·Filed 2012·Granted Jun 23, 2015·0 cites·16 claims
- 4641US8999957B2Heterocyclic compounds as ERK inhibitorsDENG YONGQI·Filed 2011·Granted Apr 7, 2015·0 cites·15 claims
- 4741US2007191604A1Novel compounds that are ERK inhibitorsCOOPER ALAN·Filed 2006·Application pending·0 cites
- 4838US2013225583A1Substituted amino-triazolyl pde10 inhibitorsSHIPPS JR GERALD W·Filed 2011·Application pending·0 cites
- 4936US2002077491A1Methods for forming combinatorial libraries combining amide bond formation with epoxide openingFiled 2001·Application pending·0 cites
- 5035US6714875B1Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validationNEOGENESIS DRUG DISCOVERY INC·Filed 1999·Granted Mar 30, 2004·3 cites·21 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gerald W. Shipps, Jr. files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →